Delivery Order SPE2DB22D2206-SPE2DB26FDR47
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $15,777.72 to AmerisourceBergen Drug Corp for the supply of Benlysta 400 mg vials, with an ultimate completion date of October 8, 2025. This competitively awarded, firm fixed-price contract represents a non-set-aside procurement and is being performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on July 25, 2025, for the supply of Benlysta 400 mg vials, with a ceiling value of $13,678.56 and firm fixed pricing. The contract is non-set-aside and competitively awarded, with an ultimate completion date of August 15, 2025. Performance will be executed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on September 26, 2025, for the supply of Benlysta 400 mg vials, with a contract ceiling value of $15,777.72. This is a firm fixed-price delivery order with an ultimate completion date of October 20, 2025. The contract was awarded on a competitive basis without any set-aside designation. AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania serves as the place of performance for...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $12,330.68 for Benlysta 200 mg/ml auto-injectors, with an ultimate completion date of September 25, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of performance is located in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a $10,518.48 delivery order to AmerisourceBergen Drug Corp for the supply of Benlysta 400 mg vials, with an ultimate completion date of August 12, 2025. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical federal medical procurement vendor for military and veteran healthcare...
- AmerisourceBergen Drug Corp has been awarded a delivery order valued at $6,165.34 by the Defense Logistics Agency's Medical Supply Chain to supply Benlysta 200 mg/ml auto-injector units. The contract is non-competitive, firm fixed-price delivery order with an ultimate completion date of September 10, 2025, and represents performance at the company's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The U.S. Department of Defense Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for $7,888.86 in Benlysta 400 mg vials on September 26, 2025, with an ultimate completion date of October 20, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger pharmaceutical supply relationship with the Defense Logistics Agency. The product will be delivered to the company's corporate office location in...
- The Defense Logistics Agency awarded a $34,196.40 delivery order to AmerisourceBergen Drug Corp for 400 mg vials of Benlysta, a therapeutic pharmaceutical used primarily in the treatment of systemic lupus erythematosus. This firm fixed-price delivery order, awarded on September 22, 2025, with an ultimate completion date of October 14, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award carries no set-aside...
- AmerisourceBergen Drug Corp has been awarded a delivery order by the Defense Logistics Agency for $6,165.36 to supply Benlysta 200 mg/ml auto-injectors, with an ultimate completion date of November 6, 2025. The contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's existing...
- The Defense Logistics Agency awarded a $2,629.64 firm fixed price delivery order to AmerisourceBergen Drug Corp for the supply of Benlysta 400 mg vials, with a completion date of June 24, 2025. This non-set-aside contract was competitively awarded on June 2, 2025, and represents a child order under AmerisourceBergen's larger pharmaceutical supply framework with DLA. The product will be delivered to the company's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB26FDR47Delivery Order
AmerisourceBergen Drug Corp has been awarded a delivery order valued at $13,678.56 by the Defense Logistics Agency (DLA) for the supply of Benlysta 400 mg vials, with an ultimate completion date of November 6, 2025. The contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating that it was competitively awarded. The award is performed from the vendor's corporate office location in Conshohocken, Pennsylvania, the company's headquarters. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a prime vendor for the DLA Medical Supply Chain, AmerisourceBergen Drug Corp supplies a comprehensive range of pharmaceutical products and medical devices to support military healthcare programs globally. The Benlysta order fulfills federal medical procurement requirements for this immunosuppressant medication used in lupus treatment, consistent with the company's extensive portfolio of specialty medications, biologics, and other critical medical commodities supporting Defense Health Agency operations and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.7k | 10/16/25 |